Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Phase 3Active, not recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of elegrobart in thyroid eye disease (TED) (2 arms), sponsored by Viridian Therapeutics. Primary endpoint: Treatment Emergent Adverse Event incidence rate at 24 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
elegrobart
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06812325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812325.